The Neutrophil to Lymphocyte Ratio Predicts the Response to Neoadjuvant Chemotherapy in Luminal B Breast Cancer.

摘要: Objective: Tumor response to neoadjuvant chemotherapy (NAC) in breast cancer (BC) patients is a predictor for overall survival. The aim of our study was determine relationship between the neutrophil lymphocyte ratio (NLR) prior NAC, BC subtypes and probability pathologic complete (pCR). Materials Methods: Medical records were collected retrospectively from Centro de Cancer at Red Salud UC-Christus. Clinical data included peripheral blood cell counts, subtype diagnosis pathology report surgery after chemotherapy. Results: A total 88 analyzed. Approximately, 25% had pCR, displayed significant correlation pCR (p= 0.0138 Chi2); this more frequent epidermal growth factor receptor type 2 (HER2) enriched (54%). Luminal B with significantly lower NLR levels (t test, p= 0.0181). Conclusions: HER2-enriched tumors higher pCR. In tumors, statistically subtype, could be useful biomarker predict tumor NAC. Further studies including other clinical parameters systemic inflammation such as platelet intratumoral or body mass index help identify that would get most benefit